课题基金 / 基金详情

MicroRNA Endotypes of Systemic Inflammation in Sub-Arachnoid hemorrhaGE (MESSAGE)

MicroRNA Endotypes of Systemic Inflammation in Sub-Arachnoid hemorrhaGE (MESSAGE)
蛛网膜下腔出血全身炎症的 MicroRNA 内型 (MESSAGE)
批准号:
9807502
负责人:
Sherry Hsiang-Yi Chou
金额:
$20.84万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-06-01 至 2021-08-20
关键词:
AcuteAffectAneurysmal Subarachnoid HemorrhagesAutoimmune DiseasesBiologicalBiological MarkersBiological ProcessBloodBlood BanksBlood CirculationBlood specimenBrain InjuriesBrain hemorrhageCase-Control StudiesCellsCerebral AneurysmCerebral IschemiaCharacteristicsChemicalsClinicalClinical TrialsCritical CareDataDestinationsDevelopmentDiseaseDisease ProgressionEconomic BurdenEpidermal Growth Factor ReceptorFunctional disorderFutureGene ExpressionHeterogeneityHumanImmuneImmune responseInflammationInflammatoryInjuryIntensive Care UnitsInterferon-betaInterleukin-6Length of StayLigandsMalignant NeoplasmsMeasurementMediatingMedicineMicroRNAsMolecular TargetMorbidity - disease rateMultiple SclerosisOrganOutcomePatient-Focused OutcomesPatientsPhasePhenotypePlasmaPopulationProspective cohortPublic HealthRandomized Clinical TrialsRheumatoid ArthritisRiskSerumSocietiesSpecific qualifier valueSpecificitySubarachnoid HemorrhageSubgroupSurvivorsSystemic Inflammatory Response SyndromeTNF geneTestingTherapeuticTissuesToll-like receptorsTreatment EfficacyUp-RegulationWomanbasebiobankbiomarker discoverybiomarker validationcandidate markerclinical careclinical developmentcohortcostcytokinedesigndisabilitydisease heterogeneityearly detection biomarkersfunctional outcomeshealth economicsimmune functionimprovedimproved outcomemacrophagemalignant breast neoplasmmicroRNA biomarkersneuroinflammationnew therapeutic targetnovelpatient populationpatient subsetspotential biomarkerpredictive modelingprospectiverecruitresponsetherapeutic miRNAtherapeutic targettranscriptomevalidation studies

项目摘要

项目成果

Sherry Hsiang-Yi Chou的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结
英文摘要
PROJECT SUMMARY Aneurysmal subarachnoid hemorrhage (SAH) is disproportionately lethal and morbid for young patients, causes extensive long-term disability, and results in significant health-economic burden to society. SAH is a heterogeneous condition. A unique feature of SAH is that, in addition to brain injury, patients can develop an acute and severe systemic illness with multiple extra-cerebral organ dysfunctions and a systemic inflammatory response syndrome. Several recent SAH clinical trials all failed to show therapeutic benefit partly due to the high degree of disease heterogeneity. A major barrier to a therapeutic breakthrough in SAH is the lack of appropriate biomarkers to identify patients most at risk for subsequent injury, complications, and bad outcome in this heterogenous population. Endotypes are biological subtypes defined by distinct pathophysiologic mechanisms that could be identified by corresponding biomarkers. Discovery of novel endotypes has led to major therapeutic breakthroughs in cancer and autoimmune diseases. MicroRNAs (miRs) are a novel class of molecules with ideal characteristics as potential biomarkers for systemic response to SAH because miRs are very stable in blood, very specific in their cells of origin and destination, can modulate biological processes in recipient cells by regulating gene expression, and are known to mediate inflammation and immune function. We have promising preliminary data showing that early increase in blood miR-26a after SAH is associated with favorable long-term outcome and possibly reduced risk for delayed cerebral ischemia (DCI), a major cause of morbidity. We hypothesize that blood miR-26a is an early biomarker for SAH long-term outcome and that miR-26a may modulate systemic inflammatory host response and reduce delayed cerebral ischemia (DCI). We propose to investigate miR-26a as a potential biomarker in an existing SAH patient cohort and biobank while simultaneously recruiting a separate, independent replication SAH cohort for prospective validation of this biomarker. As miRs may function in networks, we will explore the global blood miR transcriptome in a subset of patients to identify possible miR networks associated with SAH outcome and with DCI. To examine biological plausibility of miR- 26a in defining a novel inflammation endotype in SAH, we will explore the relationship between blood miR-26a expression and subsequent manifestations of clinical systemic inflammatory response syndrome and changes in blood inflammatory cytokine levels.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MicroRNA Endotypes of Systemic Inflammation in Sub-Arachnoid hemorrhaGE (MESSAGE)
  • 批准号:
    10704331
  • 项目类别:
  • 资助金额:
    $18.2万
  • 财政年份:
    2019
  • 负责人:
    Sherry Hsiang-Yi Chou
  • 依托单位:
Biomarkers of Vasospasm and Outcome following Subarachnoid Hemorrhage
  • 批准号:
    8251162
  • 项目类别:
  • 资助金额:
    $17.88万
  • 财政年份:
    2011
  • 负责人:
    Sherry Hsiang-Yi Chou
  • 依托单位:
Biomarkers of Vasospasm and Outcome following Subarachnoid Hemorrhage
  • 批准号:
    8600332
  • 项目类别:
  • 资助金额:
    $7.76万
  • 财政年份:
    2011
  • 负责人:
    Sherry Hsiang-Yi Chou
  • 依托单位:
Biomarkers of Vasospasm and Outcome following Subarachnoid Hemorrhage
海外基金